{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:24:23Z","timestamp":1761765863706,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81360503"],"award-info":[{"award-number":["81360503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"United Foundation of Guizhou (Qiankehe J LKZ[2013]21)"},{"DOI":"10.13039\/100005845","name":"Incubation Project for 2011 Collaborative Innovation Center for Tuberculosis Prevention and Cure in Guizhou Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006942","name":"Zunyi Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.biopha.2014.09.013","type":"journal-article","created":{"date-parts":[[2014,10,5]],"date-time":"2014-10-05T16:37:38Z","timestamp":1412527058000},"page":"917-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Newly approved integrase inhibitors for clinical treatment of AIDS"],"prefix":"10.1016","volume":"68","author":[{"given":"Wan-Gang","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2014.09.013_bib0005","first-page":"23","article-title":"Surveillance for AIDS and HIV infection among black and Hispanic children and women of childbearing age 1981\u20131989","volume":"39","author":"Gayle","year":"1990","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.biopha.2014.09.013_bib0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e3280ef6acd","article-title":"HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients","volume":"21","author":"McCutchan","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2014.09.013_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2007.43.12.1146063","article-title":"(MK-0518): an integrase inhibitor for the treatment of HIV-1","volume":"43","author":"Evering","year":"2007","journal-title":"Drugs Today"},{"key":"10.1016\/j.biopha.2014.09.013_bib0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/13543784.2012.658914","article-title":"Elvitegravir: a once-daily inhibitor of HIV-1 integrase","volume":"21","author":"Wills","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.biopha.2014.09.013_bib0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/phar.1386","article-title":"Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV","volume":"34","author":"Shah","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2014.09.013_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1517\/13543784.17.1.97","article-title":"(MK-0518): a novel integrase inhibitor for the treatment of HIV infection","volume":"17","author":"Anker","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.biopha.2014.09.013_bib0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/597290","article-title":"Raltegravir: the first HIV type 1 integrase inhibitor","volume":"48","author":"Hicks","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biopha.2014.09.013_bib0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/apc.2006.20.489","article-title":"The hunt for HIV-1 integrase inhibitors","volume":"20","author":"Lataillade","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.biopha.2014.09.013_bib0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.biopha.2014.09.013_bib0050","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.clinthera.2008.10.012","article-title":"Raltegravir: the first HIV integrase inhibitor","volume":"30","author":"Cocohoba","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.biopha.2014.09.013_bib0055","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"Summa","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopha.2014.09.013_bib0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/QAI.0b013e3181b17f53","article-title":"Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection","volume":"52","author":"Imaz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2014.09.013_bib0065","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1517\/14656560903176446","article-title":"New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir","volume":"10","author":"Hughes","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0070","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/00003495-200969080-00007","article-title":"Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients","volume":"69","author":"Croxtall","year":"2009","journal-title":"Drugs"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.biopha.2014.09.013_bib0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2047-783X-14-S3-22","article-title":"Raltegravir in treatment naive patients","volume":"14","author":"Cossarini","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.biopha.2014.09.013_bib0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/aid.2008.0222","article-title":"Raltegravir and etravirine are active against HIV type 1 group O","volume":"25","author":"Briz","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.biopha.2014.09.013_bib0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/14787210.6.4.419","article-title":"Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV","volume":"6","author":"Sayana","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.biopha.2014.09.013_bib0090","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(07)60571-6","article-title":"Raltegravir: a new antiretroviral class for salvage therapy","volume":"369","author":"Cahn","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2014.09.013_bib0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1345\/aph.1M309","article-title":"Integrase inhibitors: a novel class of antiretroviral agents","volume":"44","author":"Schafer","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-4690-6-25","article-title":"elvitegravir, and metoogravir: the birth of \u201cme-too\u201d HIV-1 integrase inhibitors","volume":"6","author":"Serrao","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.biopha.2014.09.013_bib0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"Ramanathan","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.biopha.2014.09.013_bib0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3851\/IMP1397","article-title":"Elvitegravir: a new HIV integrase inhibitor","volume":"20","author":"Shimura","year":"2009","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0115","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.01534-07","article-title":"Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137)","volume":"82","author":"Shimura","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.biopha.2014.09.013_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000233308.82860.2f","article-title":"Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients","volume":"43","author":"DeJesus","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2014.09.013_bib0125","first-page":"190","article-title":"an oral HIV integrase inhibitor, for the potential treatment of HIV infection","volume":"10","author":"Klibanov","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.biopha.2014.09.013_bib0130","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/135965350801300813","article-title":"Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine","volume":"13","author":"Ramanathan","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.biopha.2014.09.013_bib0135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/QAI.0b013e318183a982","article-title":"Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir","volume":"49","author":"Mathias","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2014.09.013_bib0140","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial","volume":"201","author":"Zolopa","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biopha.2014.09.013_bib0145","first-page":"36","article-title":"Integrase inhibitors: a clinical review of raltegravir and elvitegravir","volume":"13","author":"Grant","year":"2008","journal-title":"J HIV Ther"},{"key":"10.1016\/j.biopha.2014.09.013_bib0150","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"Cohen","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2014.09.013_bib0155","article-title":"A review of its use in adults with HIV-1 infection","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2014.09.013_bib0160","article-title":"A new integrase strand transfer inhibitor for the treatment of HIV","author":"Shah","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2014.09.013_bib0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-013-1590-9","article-title":"Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment","volume":"70","author":"Weller","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.biopha.2014.09.013_bib0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"van Lunzen","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biopha.2014.09.013_bib0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/135965350801300710","article-title":"Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy","volume":"13","author":"Buzon","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.biopha.2014.09.013_bib0180","first-page":"97","article-title":"Report from the 2008 joint ICAAC\/IDSA meeting. More on raltegravir: resistance and mechanisms of action","volume":"20","author":"Albrecht","year":"2008","journal-title":"AIDS Clin Care"},{"key":"10.1016\/j.biopha.2014.09.013_bib0185","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1128\/JVI.01168-09","article-title":"Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways","volume":"83","author":"Fransen","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.biopha.2014.09.013_bib0190","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1128\/AAC.00651-09","article-title":"Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure","volume":"53","author":"Fransen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0195","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jac\/dkp014","article-title":"Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients","volume":"63","author":"Malet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0200","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jmr.970","article-title":"IN alternative molecular recognition of DNA induced by raltegravir resistance mutations","volume":"22","author":"Mouscadet","year":"2009","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.biopha.2014.09.013_bib0205","doi-asserted-by":"crossref","first-page":"10245","DOI":"10.1128\/JVI.00894-09","article-title":"Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes","volume":"83","author":"Quercia","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.biopha.2014.09.013_bib0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jcv.2009.06.020","article-title":"Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity","volume":"46","author":"Salgado","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.biopha.2014.09.013_bib0215","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1089\/aid.2009.0039","article-title":"Dynamics of raltegravir resistance profile in an HIV type 2-infected patient","volume":"25","author":"Xu","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.biopha.2014.09.013_bib0220","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jac\/dkp310","article-title":"Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug","volume":"64","author":"Wirden","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0225","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1468-1293.2008.00628.x","article-title":"Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy","volume":"9","author":"Charpentier","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.biopha.2014.09.013_bib0230","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2014.09.013_bib0235","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.00470-08","article-title":"Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors","volume":"82","author":"Goethals","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.biopha.2014.09.013_bib0240","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/nar\/gkn1050","article-title":"The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation","volume":"37","author":"Delelis","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2014.09.013_bib0245","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1097\/QAD.0b013e32832ec4ae","article-title":"The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy","volume":"23","author":"Ferns","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2014.09.013_bib0250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jac\/dkp182","article-title":"Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen","volume":"64","author":"Ghosn","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0255","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1097\/QAD.0b013e328331a456","article-title":"etravirine and r-darunavir combination in adolescents with multidrug-resistant virus","volume":"23","author":"Thuret","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2014.09.013_bib0260","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial","volume":"49","author":"Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biopha.2014.09.013_bib0265","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkp153","article-title":"Evolution of raltegravir resistance during therapy","volume":"64","author":"Sichtig","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0270","first-page":"12","article-title":"A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing","volume":"24","author":"Bourgeois","year":"2012","journal-title":"HIV Clin"},{"key":"10.1016\/j.biopha.2014.09.013_bib0275","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States 2009\u20132012","volume":"58","author":"Hurt","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biopha.2014.09.013_bib0280","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0285","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/QAD.0000000000000199","article-title":"Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors","volume":"28","author":"Oliveira","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2014.09.013_bib0290","doi-asserted-by":"crossref","first-page":"10359","DOI":"10.1074\/jbc.271.17.10359","article-title":"Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro","volume":"271","author":"Bouziane","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopha.2014.09.013_bib0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biopha.2014.09.013_bib0300","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","article-title":"Dolutegravir a second-generation integrase inhibitor for the treatment of HIV-1 infection","volume":"48","author":"Rathbun","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0305","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14787210.2014.907525","article-title":"Dolutegravir for the treatment of adult patients with HIV-1 infection","volume":"12","author":"Wu","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.biopha.2014.09.013_bib0310","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(12)62004-2","article-title":"Dolutegravir for treatment of HIV: SPRING forwards?","volume":"381","author":"Waters","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2014.09.013_bib0315","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biopha.2014.09.013_bib0320","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2014.09.013_bib0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/07853890.2014.883169","article-title":"Integrase strand transfer inhibitors in the management of HIV-positive individuals","volume":"46","author":"Mesplede","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.biopha.2014.09.013_bib0360","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/AAC.02719-13","article-title":"Preclinical profile of BI 224436, a novel HIV-1 non-catalytic site integrase inhibitor","volume":"58","author":"Fenwick","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.biopha.2014.09.013_bib0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40265-013-0015-5","article-title":"Next-generation integrase inhibitors: where to after raltegravir?","volume":"73","author":"Karmon","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2014.09.013_bib0365","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/13543776.2014.898753","article-title":"LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006\u20132014)","volume":"24","author":"Demeulemeester","year":"2014","journal-title":"Expert Opin Ther Pathol"},{"key":"10.1016\/j.biopha.2014.09.013_bib0345","doi-asserted-by":"crossref","first-page":"e90799","DOI":"10.1371\/journal.pone.0090799","article-title":"Molecular modeling study on the allosteric inhibition mechanism of HIV-1 integrase by LEDGF\/p75 binding site inhibitors","volume":"9","author":"Xue","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2014.09.013_bib0350","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1039\/c3mb70418a","article-title":"Blocking the interaction between HIV-1 integrase and human LEDGF\/p75: mutational studies, virtual screening and molecular dynamics simulations","volume":"10","author":"Reddy","year":"2014","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.biopha.2014.09.013_bib0355","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1021\/jm401902n","article-title":"Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants","volume":"57","author":"Zhao","year":"2014","journal-title":"J Med Chem"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214001267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214001267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:55:43Z","timestamp":1760093743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332214001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0753332214001267"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2014.09.013","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newly approved integrase inhibitors for clinical treatment of AIDS","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2014.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}